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26:442–50.Early Intravenous Beta-
Blockade Before Primary
Percutaneous Coronary
Intervention Gives Major
Beneﬁts, Apparently
Without Side EffectsThe paper by Pizarro et al. (1) gives strong support
to the concept of very early low-cost intravenous
beta-blockade for primary percutaneous coronary
intervention (pPCI) and makes metoprolol the
agent of choice. When metoprolol was given to
patients with acute myocardial infarction (AMI) in
Killip class #II ST-segment elevation myocardial
infarction undergoing pPCI, there were fewer heart
failure admissions. The number needed to treat to
avoid 1 implantable cardioverter-deﬁbrillator was
only 8. Unexpectedly, there was no indication of
any side effects of beta-blockade. Were there really
none?
In the COMMIT (Clopidogrel and Metoprolol
in Myocardial Infarction Trial) study of 45,852 pa-
tients admitted to 1,250 hospitals within 24 h of
suspected AMI, patients were randomly allocated
metoprolol (up to 15 mg intravenous, then 200 mg
oral daily; n ¼ 22,929) or matching placebo (n ¼
22,923) (2). The use of early beta-blocker therapy
in AMI reduced the risks of reinfarction and ven-
tricular ﬁbrillation, yet cardiogenic shock was a
major side effect. Pizarro et al. (1) suggested starting
beta-blocker therapy only when the hemodynamic
condition had stabilized.
Yusuf (3) analyzed 28 trials involving approxi-
mately 27,500 patients during suspected early AMI.
Overall, he concluded that intravenous plus oral
beta-blockade reduced the risk for early death,
reinfarction, and ventricular ﬁbrillation by approxi-
mately 15% (3). He suggested that the reduction in
mortality was greatest for those treated within 2 h
of pain. The treated group had few side effects,
namely reversible and nonfatal heart block and
hypotension.
Thus in 2 large studies, beta-blockade had side-
effects to which clinicians should be alerted when
considering the use of beta-blockers for early AMI.*Lionel H. Opie, MD, DPhil
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Postgrad Med 1988;Spec No:90–5.REPLY: Early Intravenous Beta-Blockade
Before Primary Percutaneous Coronary
Intervention Gives Major Beneﬁts Apparently
Without Side EffectsWe appreciate the comment by our admired Professor
Opie regarding the potential side effects of early
intravenous (IV) beta-blockers in patients with
ST-segment elevation myocardial infarction (STEMI).
Our paper described the long-term follow-up of pa-
tients in the METOCARD-CNIC (Effect of Metoprolol
in Cardioprotection During an Acute Myocardial
Infarction) trial (1). The acute effects of IV metoprolol
in this trial were reported in a previous publication
(2). In the ﬁrst publication, we described the inci-
dence of adverse events during admission (those that
can be ascribed to an acute single administration of IV
metoprolol before primary angioplasty): death during
admission (2.1% vs. 2.3% in IV metoprolol vs. control,
respectively), advanced atrioventricular block (0.7%
vs. 1.5%), cardiogenic shock (4.3% vs. 5.4%), and
ventricular tachycardia/ﬁbrillation (3.6% vs. 7.7%).
Thus, it is not correct that there were no side effects
of beta-blockade in our study; rather, we presented
that metoprolol was not associated with an excess
number of these side effects.
The role of early IV beta-blockade in STEMI was
mostly evaluated long ago, and the side effect proﬁle
has been dramatically changed within the last few
years. The METOCARD-CNIC trial was the ﬁrst ran-
domized trial performed in patients with STEMI un-
dergoing reperfusion by primary angioplasty. One of
Dr. Opie’s references to support the potential increase
in side effect frequency is from Yusuf reporting a
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reperfusion era. Any comparison of the side effect
proﬁle between patients with STEMI not reperfused
by any means and those undergoing early primary
angioplasty is futile. Conversely, we agree with Dr.
Opie that the results of the COMMIT (Clopidogrel and
Metoprolol in Myocardial Infarction Trial) (3) should
be placed in perspective. We commented extensively
on the COMMIT results in our 2 previous publications,
and we refer the readers to the original publications
(1,2). To summarize, the side effects in the COMMIT
study were concentrated in patients at the highest risk
for shock: Killip class III and/or systolic hypotension
on presentation.We learned lessons from the COMMIT
study, and in the METOCARD-CNIC trial, patients
presenting with Killip class III and/or systolic blood
pressure below 120 mm Hg were contraindicated for
enrollment. Altogether, the COMMIT andMETOCARD-
CNIC trials suggest that a comprehensive selection of
patients for early IVmetoprolol treatmentmight result
in a signiﬁcant beneﬁt, with no increase in the fre-
quency of side effects. The ongoing EARLY-BAMI
(Early Beta-Blocker Administration Before Primary
PCI in Patients With ST-Elevation Myocardial Infarc-
tion) trial (Zwolle, the Netherlands) should conﬁrm the
infarct size reduction and increased long-term ven-
tricular function observed in the METOCARD-CNIC
trial. Even if conﬁrmed, infarct size and ventricular
function are surrogate markers, and a large random-
ized clinical trial with hard clinical endpoints should
be performed. The MOVE ON! (Impact of Pre-Reper-
fusion Metoprolol on Clinical Events After Myocardial
Infarction) trial will recruit more than 3,500 patients
with STEMI in 8 European countries, randomize them
to IV metoprolol or placebo during transfer to primary
angioplasty, and quantify the incidence of death or
heart failure admission over a median follow-up of 3
years. This trial will answer whether early IV meto-
prolol is the ﬁrst therapy used in conjunction with
primary angioplasty to improve clinical outcomes (4).*Borja Ibanez, MD, PhD
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Auscultatory Biomarker
or Imaging Biomarker?We read with interest the paper by Coffey et al.
(1) reporting the results of a meta-analysis on the
prevalence, incidence, and risks of aortic valve scle-
rosis (ASc). In this review, the authors demonstrated
that ASc is common in the general population and
is independently associated with an increased fre-
quency of major adverse cardiovascular and cere-
brovascular events (MACCE), as well as all-cause
mortality, making it a powerful “imaging biomarker.”
The researchers analyzed studies that deﬁned
ASc as any thickening or calciﬁcation of the aortic
valve—detectable by any means, such as transthoracic
or transesophageal echocardiogram or computed
tomography—without any signiﬁcant hemodynamic
effect. Although not directly addressing the results of
this meta-analysis, we want to take this opportunity
to address that mindful auscultation can lead one
in the right direction hours, days, and even weeks
before the same results can be achieved by those
who rely solely on modern technology.
We have a wonderfully rich tradition of physical
diagnostic signs in cardiology. However, in contem-
porary medicine, many have come to rely solely on
clinical imaging and laboratory testing, looking at
physical diagnostic signs askance and thus neglecting
or even discarding knowledge acquired during
clinical training. Disregard for physical diagnostic
methods now pervades clinical training in the United
States, and the art of physical diagnosis has been
reduced to a mere vestige, with several experts con-
tending that physical diagnosis has little to offer the
modern clinician. This is particularly true of the
stethoscope, which some believe should be exiled to
the archives of medical history.
Without distracting the readers from the results
of this meta-analysis (1), it is important to note
